Adaptimmune Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Adaptimmune Therapeutics generated cash of -$140,880,000, which is more than the previous year. Cash used in financing activities reached the amount of $880,000 last year. Net change in cash is therefore $37,415,000.
Cash Flow
| 2014 | 37.23M | -1.44M | 16.93M |
|---|---|---|---|
| 2015 | -32.73M | -60.28M | 0 |
| 2016 | -48.16M | 17.75M | 17K |
| 2017 | -54.31M | -126.08M | 103.56M |
| 2018 | -104.38M | -17.45M | 102.69M |
| 2019 | -112.50M | 94.94M | 366K |
| 2020 | -53.59M | -278.92M | 340.05M |
| 2021 | 10.72M | 75.8M | 3.28M |
| 2022 | -141.76M | 89.13M | 12.86M |
| 2023 | -140.88M | 176.53M | 880K |
ADAP Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 109.60M | 151.66M | 61.48M | 54.90M | 72.47M | 88.29M | 162.79M | 198.77M | 47.34M | -1.44M |
Operating activities | ||||||||||
Net income | -113.87M | -165.45M | -158.09M | -130.09M | -137.16M | -95.51M | -70.13M | -71.57M | -23.69M | -14.37M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 9.45M | 6.07M | 6.56M | 7.59M | 8.01M | 7.81M | 5.42M | 3.28M | 732.78K | 250.36K |
Stock-based compensation expense | 11.77M | 18.24M | 20.62M | 10.41M | 11.05M | 0 | 10.80M | 8.82M | 4.21M | 349.15K |
| Deferred income tax benefit | 11.77M | 18.24M | 20.62M | 10.41M | 11.05M | 0 | 10.80M | 8.82M | 4.21M | 349.15K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | -9.80M | -19.35M | 1.76M | -1.44M | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 5.40M | 15.14M | -5.65M | -6.19M | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 0 | 4.40M | 4.20M | 3.89M | 7.63M | 0 | 0 | 0 | 0 | 0 |
Cash generated by operating activities | -140.88M | -141.76M | 10.72M | -53.59M | -112.50M | -104.38M | -54.31M | -48.16M | -32.73M | 37.23M |
Investing activities | ||||||||||
Purchases Of Investments | -76.24M | -48.11M | -139.76M | -381.04M | -27.28M | -150.78M | -171.33M | -42.83M | -55.29M | 0 |
Investments In Property Plant And Equipment | -4.68M | -29.74M | -8.78M | -2.90M | -3.07M | -4.70M | -25.01M | -12.78M | -5.10M | -1.44M |
Acquisitions Net | 0 | 77.85M | 207K | 565K | 1.48M | 798K | 369K | 1.27M | 0 | 0 |
Cash generated by investing activities | 176.53M | 89.13M | 75.8M | -278.92M | 94.94M | -17.45M | -126.08M | 17.75M | -60.28M | -1.44M |
Financing activities | ||||||||||
Common Stock Issued | 624K | 12.81M | 3.28M | 342.69M | 367.51K | 99.65M | 103.16M | 0 | 0 | 16.93M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 880K | 12.86M | 3.28M | 340.05M | 366K | 102.69M | 103.56M | 17K | 0 | 16.93M |
Net Change In Cash | 37.41M | -42.06M | 90.18M | 6.57M | -17.56M | -15.82M | -74.5M | -35.97M | 181.71M | 52.71M |
Cash at end of period | 147.01M | 109.60M | 151.66M | 61.48M | 54.90M | 72.47M | 88.29M | 162.79M | 229.05M | 51.27M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |